Edition:
United States

Vermillion Inc (VRML.OQ)

VRML.OQ on NASDAQ Stock Exchange Capital Market

2.14USD
24 Mar 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.14
Open
$2.17
Day's High
$2.20
Day's Low
$2.08
Volume
10,279
Avg. Vol
22,699
52-wk High
$2.85
52-wk Low
$0.76

Latest Key Developments (Source: Significant Developments)

Vermillion say co, unit entered amendment No. 2 to testing, services agreement with Quest Diagnostics effective March 11, 2017
Monday, 13 Mar 2017 04:40pm EDT 

Vermillion Inc : Vermillion - co, unit entered amendment no. 2 to testing and services agreement with quest diagnostics incorporated effective March 11, 2017 .Vermillion Inc - primary purpose of amendment was to extend initial term of testing and services agreement from March 11, 2017 to March 11, 2018.  Full Article

Vermillion announces reimbursement code updates for Overa and OVA1
Monday, 9 Jan 2017 09:00am EST 

Vermillion Inc :Vermillion Inc - Co and unit Aspira Labs, have received a proprietary laboratory analyses (PLA) code (0003U) for Overa (MIA2G).  Full Article

Vermillion Q3 revenue $623,000
Thursday, 10 Nov 2016 04:03pm EST 

Vermillion Inc : Vermillion Inc - expect net cash utilization to be less than $3.0 million in Q4 of 2016 . Vermillion reports third quarter 2016 results . Q3 loss per share $0.07 .Q3 revenue $623,000 versus $330,000.  Full Article

Vermillion reports Q2 loss per share $0.07
Wednesday, 10 Aug 2016 07:30am EDT 

Vermillion Inc : Vermillion reports second quarter 2016 results . Q2 loss per share $0.07 .Q2 revenue $709,000 versus $535,000.  Full Article

Vermillion Inc Q1 loss per share $0.09
Monday, 16 May 2016 04:15pm EDT 

Vermillion Inc : Expect net cash utilization of $2.0 million - $3.0 million in q2 of 2016 . Vermillion reports first quarter 2016 results .Q1 loss per share $0.09.  Full Article

Vermillion, Inc announces FDA Clearance of Overa®
Monday, 21 Mar 2016 08:15am EDT 

Vermillion, Inc:Says Receipt of 510(k) marketing clearance from the FDA for successor to Vermillion's OVA1® test for determining ovarian cancer risk in conjunction with independent clinical and imaging assessment prior to planned surgery for a women with a pelvic mass.Says Second Generation OVA1 test, previously referred to as "OVA2", has been trademarked "Overa®.Overa replaces two of the five OVA1 biomarkers with HE4 and FSH in order to improve specificity and reduce the need for physicians to determine menopausal status when interpreting the test.  Full Article

Vermillion Inc adopts restructuring plan - Reuters
Friday, 12 Feb 2016 04:26pm EST 

Vermillion Inc:Restructuring headcount,other expenses targeting about 20% reduction in operating expenses in 2016 versus operating expenses in 2015 - RTRS.Says adopted a restructuring plan to streamline its organization - SEC filing.  Full Article

Vermillion, Inc announces closing of $18.8 mln public offering of common stock
Friday, 17 Jul 2015 11:00am EDT 

Vermillion, Inc:Closes public offering of 9,602,500 shares of its common stock, including 1,252,500 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares at a price to the public of $1.96 per share.Says Canaccord Genuity acted as sole book-running manager and Roth Capital Partners acted as lead manager for the offering.Net proceeds from the sale of the shares of common stock, after deducting the underwriting discount and the other offering expenses, are expected to be about $17.5 mln.Intends to use the net proceeds from the offering to fund domestic and international commercialization, bioinformatics platform enhancements, portfolio expansion and general corporate purposes.  Full Article

Vermillion Inc prices $16.4 mln public offering of common stock
Tuesday, 14 Jul 2015 09:00am EDT 

Vermillion Inc:Prices $16.4 mln public offering of common stock.Says public offering of 8.4 mln common shares priced at $1.96 per share.Canaccord Genuity is acting as sole book-running manager and Roth Capital Partners is acting as lead manager for offering.Net proceeds from sale of shares of common stock, after deducting the underwriting discount and commissions and the other offering expenses, are expected to be about $15.2 mln.Vermillion intends to use net proceeds from offering to fund domestic and international commercialization, bioinformatics platform enhancements, portfolio expansion and general corporate purposes.  Full Article

Vermillion announces proposed public offering of common stock
Monday, 13 Jul 2015 04:01pm EDT 

Vermillion:intends to offer shares of its common stock in an underwritten public offering.offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.All of the shares will be offered by Vermillion.Canaccord Genuity is acting as sole book-running manager and Roth Capital Partners is acting as lead manager for the offering.Vermillion, Inc. intends to use the net proceeds from the offering to fund domestic and international commercialization, bioinformatics platform enhancements, portfolio expansion and general corporate purposes.  Full Article

More From Around the Web

BRIEF-Vermillion say co, unit entered amendment No. 2 to testing, services agreement with Quest Diagnostics effective March 11, 2017

* Vermillion - co, unit entered amendment no. 2 to testing and services agreement with quest diagnostics incorporated effective March 11, 2017